Halozyme Therapeutics, Inc. HALO.MX Stock
Halozyme Therapeutics, Inc. Price Chart
Halozyme Therapeutics, Inc. HALO.MX Financial and Trading Overview
Halozyme Therapeutics, Inc. stock price | 680 MXN |
Previous Close | 679.74 MXN |
Open | 0 MXN |
Bid | 0 MXN x N/A |
Ask | 0 MXN x N/A |
Day's Range | 679.74 - 679.74 MXN |
52 Week Range | 679.74 - 679.74 MXN |
Volume | 0 MXN |
Avg. Volume | 0 MXN |
Market Cap | 124.53B MXN |
Beta (5Y Monthly) | 1.216901 |
PE Ratio (TTM) | 12.406278 |
EPS (TTM) | 31.96 MXN |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
HALO.MX Valuation Measures
Enterprise Value | 90.76B MXN |
Trailing P/E | 12.406278 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 176.64485 |
Price/Book (mrq) | 1359.48 |
Enterprise Value/Revenue | 128.743 |
Enterprise Value/EBITDA | 272.652 |
Trading Information
Halozyme Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.216901 |
52-Week Change | 0% |
S&P500 52-Week Change | 20.43% |
52 Week High | 679.74 MXN |
52 Week Low | 679.74 MXN |
50-Day Moving Average | 679.74 MXN |
200-Day Moving Average | 679.74 MXN |
HALO.MX Share Statistics
Avg. Volume (3 month) | 0 MXN |
Avg. Daily Volume (10-Days) | 0 MXN |
Shares Outstanding | 131.68M |
Float | 130.46M |
Short Ratio | N/A |
% Held by Insiders | 0.91% |
% Held by Institutions | 97.66% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 25.76% |
Operating Margin (ttm) | 37.95% |
Gross Margin | 67.19% |
EBITDA Margin | 47.21% |
Management Effectiveness
Return on Assets (ttm) | 11.68% |
Return on Equity (ttm) | 111.39% |
Income Statement
Revenue (ttm) | 704.98M MXN |
Revenue Per Share (ttm) | 5.18 MXN |
Quarterly Revenue Growth (yoy) | 38.29% |
Gross Profit (ttm) | 454.21M MXN |
EBITDA | 332.88M MXN |
Net Income Avi to Common (ttm) | 181.64M MXN |
Diluted EPS (ttm) | 54.79 |
Quarterly Earnings Growth (yoy) | -34.10% |
Balance Sheet
Total Cash (mrq) | 275.61M MXN |
Total Cash Per Share (mrq) | 2.09 MXN |
Total Debt (mrq) | 1.53B MXN |
Total Debt/Equity (mrq) | 2321.1 MXN |
Current Ratio (mrq) | 6.691 |
Book Value Per Share (mrq) | 0.5 |
Cash Flow Statement
Operating Cash Flow (ttm) | 279.28M MXN |
Levered Free Cash Flow (ttm) | 175.3M MXN |
Profile of Halozyme Therapeutics, Inc.
Country | Mexico |
State | CA |
City | San Diego |
Address | 12390 El Camino Real |
ZIP | 92130 |
Phone | 858 794 8889 |
Website | https://halozyme.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 393 |
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Q&A For Halozyme Therapeutics, Inc. Stock
What is a current HALO.MX stock price?
Halozyme Therapeutics, Inc. HALO.MX stock price today per share is 680 MXN.
How to purchase Halozyme Therapeutics, Inc. stock?
You can buy HALO.MX shares on the Mexico exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Halozyme Therapeutics, Inc.?
The stock symbol or ticker of Halozyme Therapeutics, Inc. is HALO.MX.
Which industry does the Halozyme Therapeutics, Inc. company belong to?
The Halozyme Therapeutics, Inc. industry is Biotechnology.
How many shares does Halozyme Therapeutics, Inc. have in circulation?
The max supply of Halozyme Therapeutics, Inc. shares is 127.05M.
What is Halozyme Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Halozyme Therapeutics, Inc. PE Ratio is 21.27659600 now.
What was Halozyme Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Halozyme Therapeutics, Inc. EPS is 31.96 MXN over the trailing 12 months.
Which sector does the Halozyme Therapeutics, Inc. company belong to?
The Halozyme Therapeutics, Inc. sector is Healthcare.